期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 75, 期 1, 页码 15-26出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2009.09.008
关键词
Metastatic colorectal cancer; Management; Cytotoxic drugs; Cetuximab; Bevacizumab
The prognosis of patients with metastatic colorectal cancer has significantly improved in the last few years, with the introduction into the clinical practice of new cytotoxic treatments, the availability of non-cross resistant agents after the front-line treatment failure, and the combination of targeted agents (i.e., the inhibitors of the epidermal growth factor and vascular endothelial growth factor pathways) with conventional drugs. All these options must be incorporated into a complex strategy of management, in which a customized management according to the disease status, with an intensified induction approach followed by maintenance (and reinduction), should be investigated. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据